INCYTE CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.79 USD | +0.86% |
|
+0.84% | -7.96% |
| 05-23 | Deutsche Bank Initiates Incyte to Hold Rating With $55 Price Target | MT |
| 05-21 | Incyte Acquires 2 Office Buildings in Delaware | MT |
Presenter SpeechTazeen Ahmad (Analysts)Welcome to Day 2 of the Bank of America Healthcare Conf...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
Pharmaceuticals
Calendar
10/06/2024
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
57.79
USD
Average target price
72.8
USD
Spread / Average Target
+25.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.96% | 12.99B | |
| -2.29% | 89.87B | |
| -3.95% | 37.57B | |
| -13.07% | 32.75B | |
| +63.05% | 26.47B | |
| -22.14% | 14.25B | |
| -9.33% | 11.93B | |
| -46.33% | 10.84B | |
| +5.77% | 9.11B | |
| -17.66% | 7.32B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Transcript : Incyte Corporation Presents at Bank of America Health Care Conference 2024, May-15-2024 08
